Located in Sant Fost de Campsentelles (Barcelona), it has a productive chemical plant, a very modern Pilot Plant equipped with various technology; several R+D laboratories, and a Quality Control laboratory.
At Urquima, both NCE's, such as Triflusal, Rupatadine, Flutrimazol, etc. and General Pharmaceutical Active Ingredients such as Glipicide, Ropinirol, Glimepiride, among others, are developed and produced on an industrial scale. These products are part of the regular production, and others are currently in the advanced stages of development or industrialisation.
The plant has been awarded the ISO 9001:2008 certificate. Its operations and systems are regularly inspected by national (AEMPS) and international (FDA) health care agencies, and by national and international clients. This guarantees that the GMP, ICHQ7A part II standard is strictly observed and, in turn, this satisfies the most demanding market standards.
The chemical plant has a reaction capacity of 153m3, and it is a multi-product plant that produces more than 70 tonnes per year of pharmaceutical active ingredients (PAI) for various therapeutic areas.
At the end of 2010, URQUIMA, S.A., set up a Joint venture with SUNLIGHT PHARMACEUTICAL, a company that manufactures intermediate fine chemistry products and pharmaceutical active ingredients, and which is based in China. This alliance has introduced the Uriach Group to Asia, which is considered one of the markets with greater future projection.